KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evolent Health (EVH) EBITDA (2016 - 2026)

Evolent Health has reported EBITDA over the past 11 years, most recently at -$429.4 million for Q4 2025.

  • For Q4 2025, EBITDA fell 1285.05% year-over-year to -$429.4 million; the TTM value through Dec 2025 reached -$580.3 million, down 517.64%, while the annual FY2025 figure was -$580.3 million, 517.64% down from the prior year.
  • EBITDA for Q4 2025 was -$429.4 million at Evolent Health, down from -$27.6 million in the prior quarter.
  • Over five years, EBITDA peaked at $1.9 million in Q3 2022 and troughed at -$429.4 million in Q4 2025.
  • A 5-year average of -$43.7 million and a median of -$25.7 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: skyrocketed 114.28% in 2022 and later crashed 1891.89% in 2023.
  • Year by year, EBITDA stood at -$5.6 million in 2021, then plummeted by 103.38% to -$11.5 million in 2022, then tumbled by 260.42% to -$41.4 million in 2023, then rose by 25.09% to -$31.0 million in 2024, then tumbled by 1285.05% to -$429.4 million in 2025.
  • Business Quant data shows EBITDA for EVH at -$429.4 million in Q4 2025, -$27.6 million in Q3 2025, and -$51.1 million in Q2 2025.